289 related articles for article (PubMed ID: 10783936)
1. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
[TBL] [Abstract][Full Text] [Related]
2. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004
[TBL] [Abstract][Full Text] [Related]
3. The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.
Bilde L; Rud Svenning A; Dollerup J; Baekke Borgeskov H; Lange P
Respir Med; 2007 Mar; 101(3):539-46. PubMed ID: 16889949
[TBL] [Abstract][Full Text] [Related]
4. [Pharmaco-economics of asthma and chronic obstructive lung disease].
Jahnz-Rózyk K; Targowski T; From S; Debowski T
Pol Merkur Lekarski; 2003 Jun; 14(84):676-8. PubMed ID: 14524302
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
Chiang CH
Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
[TBL] [Abstract][Full Text] [Related]
6. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
7. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
9. Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden.
Tunsäter A; Moutakis M; Borg S; Persson U; Strömberg L; Nielsen AL
Health Policy; 2007 May; 81(2-3):309-19. PubMed ID: 16904788
[TBL] [Abstract][Full Text] [Related]
10. History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden.
Sadatsafavi M; Tavakoli H; Kendzerska T; Gershon A; To T; Aaron SD; FitzGerald JM;
Ann Am Thorac Soc; 2016 Feb; 13(2):188-96. PubMed ID: 26599154
[TBL] [Abstract][Full Text] [Related]
11. The economic consequences of asthma among adults in Sweden.
Jansson SA; Rönmark E; Forsberg B; Löfgren C; Lindberg A; Lundbäck B
Respir Med; 2007 Nov; 101(11):2263-70. PubMed ID: 17689234
[TBL] [Abstract][Full Text] [Related]
12. Health economic costs of COPD in Sweden by disease severity--has it changed during a ten years period?
Jansson SA; Backman H; Stenling A; Lindberg A; Rönmark E; Lundbäck B
Respir Med; 2013 Dec; 107(12):1931-8. PubMed ID: 23910072
[TBL] [Abstract][Full Text] [Related]
13. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect costs of asthma in Canada, 1990.
Krahn MD; Berka C; Langlois P; Detsky AS
CMAJ; 1996 Mar; 154(6):821-31. PubMed ID: 8634960
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].
Jahnz-Rózyk K; Targowski T; From S
Pneumonol Alergol Pol; 2008; 76(6):426-31. PubMed ID: 19173191
[TBL] [Abstract][Full Text] [Related]
16. [Projections of future resource use and the costs of asthma and COPD in the Netherlands].
Hoogendoorn M; Feenstra TL; Rutten-van Mölken MP
Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1243-50. PubMed ID: 16796176
[TBL] [Abstract][Full Text] [Related]
17. Cost and utilization of COPD and asthma among insured adults in the US.
Blanchette CM; Broder M; Ory C; Chang E; Akazawa M; Dalal AA
Curr Med Res Opin; 2009 Jun; 25(6):1385-92. PubMed ID: 19419342
[TBL] [Abstract][Full Text] [Related]
18. Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
Akazawa M; Halpern R; Riedel AA; Stanford RH; Dalal A; Blanchette CM
Respir Med; 2008 Dec; 102(12):1744-52. PubMed ID: 18760581
[TBL] [Abstract][Full Text] [Related]
19. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
Mittmann N; Kuramoto L; Seung SJ; Haddon JM; Bradley-Kennedy C; Fitzgerald JM
Respir Med; 2008 Mar; 102(3):413-21. PubMed ID: 18086519
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].
Faber M; Jahnz-Rózyk K; Kucharczyk A; Targowski T; From S; Mamełka B
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():96-9. PubMed ID: 15524029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
